{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:28:51Z","timestamp":1762651731644,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmorw.2025.100149","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:54:58Z","timestamp":1748332498000},"page":"100149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-354X","authenticated-orcid":false,"given":"B.","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gayle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Damineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kebede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2025.100149_bib2","first-page":"1","article-title":"Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: summary of level 1 evidence and current gaps in knowledge","volume":"37","author":"Baude","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100149_bib3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.esmorw.2025.100149_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100149_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41585-020-0335-7","article-title":"Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer","volume":"17","author":"Perera","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.esmorw.2025.100149_bib6","article-title":"Cancer registry data linkage of electronic health record data from ASCO\u2019s CancerLinQ: evaluation of advantages, limitations, and lessons learned","volume":"6","author":"Charlton","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.esmorw.2025.100149_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/CCI.20.00064","article-title":"Development of CancerLinQ, a health information learning platform from multiple electronic health record systems to support improved quality of care","volume":"4","author":"Potter","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"21","key":"10.1016\/j.esmorw.2025.100149_bib8","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in black men with prostate cancer: a literature review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100149_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50416","article-title":"Evaluation of social determinants of health and prostate cancer outcomes among black and white patients: a systematic review and meta-analysis","volume":"6","author":"Vince","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"suppl 6","key":"10.1016\/j.esmorw.2025.100149_bib10","volume":"40","author":"Kibel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100149_bib11","first-page":"13","article-title":"Architecture and implementation of a clinical research data warehouse for prostate cancer","volume":"6","author":"Seneviratne","year":"2018","journal-title":"EGEMS (Wash DC)"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100149_bib12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/curroncol30020143","article-title":"Harnessing real-world evidence to advance cancer research","volume":"30","author":"Tang","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmorw.2025.100149_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.873556","article-title":"Challenges and opportunities with routinely collected data on the utilization of cancer medicines. Perspectives from health authority personnel across 18 European countries","volume":"13","author":"Pisana","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100149_bib14","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100149_bib15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:25:51Z","timestamp":1762651551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":14,"alternative-id":["S2949820125000384"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100149","relation":{},"ISSN":["2949-8201"],"issn-type":[{"type":"print","value":"2949-8201"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100149"}}